Fig. 6: Knockdown of BCAT1 increases cisplatin sensitivity in vivo. | Cell Death & Disease

Fig. 6: Knockdown of BCAT1 increases cisplatin sensitivity in vivo.

From: BCAT1 decreases the sensitivity of cancer cells to cisplatin by regulating mTOR-mediated autophagy via branched-chain amino acid metabolism

Fig. 6

A Representative images of the xenograft tumors (n = 5). HepG2 cells with BCAT1 knockdown by shBCAT1 or control cells were subcutaneously implanted into nude mice. Seven days later, the mice were treated daily with intraperitoneally injections of the diluents or cisplatin for 27 days. B Tumor volume was measured and calculated every 3 days (n = 5). C The final tumor weight was measured (n = 5). D The body weight of mice was measured every 3 days (n = 5). E The protein expression levels of BCAT1, LC3B-I/II, mTOR, and phosphorylated mTOR were examined in the tumor tissues by Western blot. F IHC staining of Ki-67 and cleaved caspase-3 and TUNEL assay. The arrow represents a positive signal. Scale bars: 50 μm. **P < 0.01, ***P < 0.001.

Back to article page